Physician profile
Fariba E Parmer
NPI 1467621516
$25,500.93
in general payments reported to CMS, 2019-2025
18 companies · $11K in 2025
The $11K reported for 2025 was more than what 98% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,249 · 2020: $31.52 · 2021: $302 · 2022: $365 · 2023: $583 · 2024: $9,593 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Food and Beverage: $4,296 · Travel and Lodging: $2,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,000.00 |
| Food and Beverage | $4,296.27 |
| Travel and Lodging | $2,257.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $19,465.70 | 2022-2025 | Miebo, Xiidra, Blink Nutritears |
| Shire North American Group INC | $3,110.31 | 2019 | |
| Alcon Vision LLC | $375.73 | 2021-2025 | Tryptyr, Rocklatan, Eysuvis |
| Biotissue Holdings INC. | $361.42 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $354.00 | 2020-2025 | Cequa |
| Harrow Eye, LLC | $335.19 | 2024-2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $326.07 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $249.77 | 2019-2023 | |
| Dompe US, INC. | $233.49 | 2022-2025 | Oxervate |
| Johnson & Johnson Surgical Vision, INC. | $200.72 | 2021-2025 | Veritas Vision System, Tecnis Simplicity, Tecnis Iol |
| Abbvie INC. | $184.46 | 2022-2025 | |
| Allergan, INC. | $107.90 | 2021-2022 | |
| Oyster Point Pharma, INC. | $53.11 | 2023 | Tyrvaya |
| Rayner Intraocular Lenses Limited | $38.03 | 2022-2025 | Rayone Spheric, Rayner Cataract Set 1, Rayone Aspheric |
| Kala Pharmaceuticals, INC. | $37.27 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $31.56 | 2025 | Tearcare System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.84 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fariba Parmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.